Google
Trusted Resources: News & Events
Latest announcements and gatherings
Public Meeting on Patient-Focused Drug Development for Chronic Pain
Meeting Information:
On July 9, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain.
Date: July 9, 2018
Time: 10:00 a.m. – 4:00 p.m. (registration will begin at 9:00am)
Location:
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
This event has ended.
+myBinderRelated Content
-
Splenectomy to optimize hemoglobin s control in children with sickle cell disease on chronic transfusion therapy for...Background: Consensus guidelines recomme...
-
Effects of Hydroxyurea Treatment for Patients With Hemoglobin SC DiseaseAlthough hemoglobin SC (HbSC) disease is...
-
ASH Clinical Practice Guidelines on Sickle Cell Disease (SCD)https://www.youtube.com/watch?v=tozUcTSN...
-
Hydroxyurea improves lung function in children with sickle cell diseaseFor the first time, researchers were abl...
-
FDA agrees accelerated approval pathway for GBT’s voxelotorGlobal Blood Therapeutics, Inc. ...
-
Cayenne Wellness Center’s 15th Annual Sickle Cell Disease Educational SummitCayenne Wellness Center’s Annual Sickl...
-
Statement from FDA Commissioner on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.